Intas: Strategic Acquisition of Prothya Biosolutions to Expand Global Market Presence
Deal News | Aug 11, 2025 | PR Newswire Cision Accord Healthcare
Intas Pharmaceuticals Ltd, through its subsidiary Accord Plasma B.V., has announced the acquisition of Prothya Biosolutions Belgium BV, a leading company in the plasma-derived medicinal products (PDMP) sector. This acquisition includes Prothya's operations in the Netherlands and Belgium, along with plasma collection centers in Hungary and over 1,200 employees. Prothya was formed from a 2021 integration of Plasma Industries Belgium and Sanquin Plasma Products, carrying over 60 years of experience in the field. This strategic move by Intas is intended to enhance its global presence in the PDMP market, leveraging its existing capabilities in India to serve a worldwide clientele. As global demand for PDMPs, particularly IVIG, is projected to rise significantly, the acquisition positions Intas favorably in the growing market. Financial advisory services are being provided by BofA Securities and Evercore for Accord and Prothya respectively.
Sectors
- Pharmaceuticals
- Healthcare
- Biotechnology
Geography
- India – Intas Pharmaceuticals, the acquiring company, is headquartered in India, making it a significant geographical focus.
- Belgium – Prothya Biosolutions is based in Belgium, marking it as a key geographical location involved in the acquisition.
- Netherlands – Prothya Biosolutions has significant operations in the Netherlands, making it a relevant geographical area.
- Hungary – Prothya's plasma collection centers are located in Hungary, indicating its importance in the geographical classification.
Industry
- Pharmaceuticals – The article focuses on the acquisition within the pharmaceutical sector, specifically involving plasma-derived medicinal products.
- Healthcare – The acquisition emphasizes the expansion of global healthcare access and the production of medical therapies, notable aspects of the healthcare industry.
- Biotechnology – Prothya's specialization in plasma-derived products and medicinal innovations aligns with the biotechnology industry's focus on biological and medicinal products development.
Financials
- $30 billion – Current valuation of the global market for PDMPs, particularly IVIG.
- $50 billion – Expected valuation of the PDMP global market by 2035.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Intas Pharmaceuticals Ltd. | Bidding Company | Company | A leading pharmaceutical company based in India, acquiring Prothya to expand its global PDMP market presence. |
| Accord Plasma B.V. | Investment Vehicle | Company | A subsidiary of Intas Pharmaceuticals, responsible for executing the acquisition of Prothya Biosolutions. |
| Prothya Biosolutions Belgium BV | Target Company | Company | A major player in the plasma-derived medicinal products sector, operating primarily in Belgium and the Netherlands. |
| BofA Securities | Financial Advisor | Company | Providing financial advisory services to Accord in this transaction. |
| Evercore | Financial Advisor | Company | Serving as the exclusive financial advisor to Prothya in the acquisition process. |
| Binish Chudgar | Chairman | Person | Chairman of Intas & Accord, involved in the strategic direction of the acquisition. |
| Nir Epstein | CEO | Person | CEO of Prothya Biosolutions, overseeing operations and business strategy. |